Bladder Cancer Weekly

April 27, 2026

Videos

Peer-to-Peer Clinical Conversations

Prospective Study Investigates ctDNA as an Adjunct to Endoscopic Evaluation Before Cystectomy - Matthew Zibelman

Matthew Zibelman

Matthew Zibelman outlines a post-hoc ctDNA analysis drawn from a prospective study of systematic endoscopic evaluation before radical cystectomy in 54 patients with bladder cancer.

View

Design and Safety of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec - Sarah Psutka

Sarah Psutka

Sarah Psutka discusses cretostimogene grenadenorepvec expanded access program with Ashish Kamat.

View

Beyond the Abstracts

Contemporary Practice Patterns in Female Radical Cystectomy: Results of a UK and Ireland Survey - Beyond the Abstract

Bladder Preservation after Neoadjuvant Therapy for Muscle-invasive Bladder Cancer in the Current Era: Myth and Reality - Beyond the Abstract

Conference Coverage

EAU 2026: TMT for MIBC: Radiation, Responsibility, and Recurrences -- Who Manages the Fallout, and How? Debater 2: Toxicity Happens but Is Manageable -- Radiation Oncologists Can and Should Take Responsibility

SES AUA 2026: Physician Experiences with the Gemcitabine Intravesical System in High Risk NMIBC: A Qualitative Study of SunRISe Trial Investigators 

EAU 2026: Trial Highlights: ALBAN - Atezolizumab + BCG (Negative)

EAU 2026: Bladder Preservation Post-neoadjuvant Chemotherapy: A Smart Strategy or Risky Business?

ASCO GU 2026: Sasanlimab + BCG in BCG-Naïve High Risk NMIBC: Exploratory Biomarker Analysis of the Phase 3 CREST Trial

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Fatty Acid Intake and Bladder Cancer Risk: A Multicenter Case-Control Study in Iran.

Detrimental effect of delayed or incomplete BCG protocols administration after trans-urethral tumor resection in patients with non-muscle-invasive bladder cancer: a systematic review.

Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in people undergoing radical cystectomy.

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer.

Venous thromboembolism in patients with urothelial carcinoma receiving systemic therapy.

Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the U

A Study to Evaluate Efficacy and Safety of Hydeal Cyst Intravesical Instillations in Non-muscle Invasive Bladder Cancer Patients Treated With Intravesical Chemotherapy or Immunotherapy.

Long-Term Outcomes of Partial Cystectomy for Urothelial Carcinoma In the Era of Bladder Preservation.

Association of patient, disease, and structural characteristics with receipt of intravesical BCG therapy from 2002-2017 and the impact of BCG supply shortages.

Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer.

Oncological Outcomes of Epirubicin-based Hyperthermic Intravesical Chemotherapy in Bacillus Calmette-Guérin (BCG)-naïve Patients and Patients with BCG Failure: A Multicenter Retrospective Observational Study.

Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial - Beyond the Abstract

The role of Bladder EpiCheck® test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study.

Alternatives to radical cystectomy: a bladder-sparing approach in appropriately selected patients.

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Implications of Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score as a Predictor of Neoadjuvant Chemotherapy Response in Bladder Cancer Patients - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login